NorthWest Biotherapeutics Inc (NWBO)

[hyperopia]

ski, the general deadline for SNO abstracts was June 1st. I think the abstract is based on the more in-depth journal article, so it seems probable that the article was submitted prior to this date as well. It would be nice (and make sense) if the long-awaited article was coordinated with the SNO presentation, so that all the top neuro-oncologists from around the world attending the meeting, patients, patient advocates, and investment community, are finally able to fully understand and discuss the merits of the trial, and the newest treatment option; but who knows? Some may believe that the 50 authors, and new generic name are indications of this, but it’s actually in this SNO guidelines:

* General Abstract Deadline is Wednesday, June 1, 2022, 11:59pm EDT

* Abstract Guidelines
• Abstract Title:
o Should be sentence case (i.e., only the first letter of the title should be capitalized) o Should be plain text (No html)
o Word Limit: 75 words/ 200 characters
• Abstract Body:o Word Limit: 300 words
o Figures and tables are not allowed
o Should be in a single paragrapho If subheaders are used, they should be within that single paragraph in all-caps, not bolded (e.g.,
METHODS:
o If you use the greater than/equal to symbol, you MUST put a space before entering the number.
o Abstracts should be data-driven and must include this information in the body of the abstract.
o Please be sure to carefully check your abstract for content errors, spelling, names, etc. before
submitting. SNO neither proofreads for nor corrects spelling, typographical, grammatical, or scientific errors.
• Authors:
o There can only be 1 presenting author per submission.
o There is a maximum of 50 authors per abstract submission.
o Only the presenting author is required to submit a Conflict of Interest Disclosure.
o Enter the names of authors in the order in which you wish them to appear in the printed text.
o Presenting Authors will need to complete new Presenting Author Task.
• Educational Objectives:
o Must provide 2-3 objectives
o Word Limit: 30 words per objective
* For information and special guidelines on Late-Breaking Abstracts, click here.
* General Guidelines:
o Please make sure your abstract contains only generic drugs names. Abstracts with trade names in the title or body could be precluded from presentation.
o Please be sure to carefully check your submission for content errors. SNO neither proofreads for nor corrects spelling, typographical, grammatical, or scientific errors. Errors made on your submitted abstract are likely to appear in print.
o Please be sure to verify the presenters email address. All communication regarding the abstract will be sent to the presenting author’s email address that was entered at the time of submission.

https://files.constantcontact.com/feea4795801/e3df7af8-0abf-4b5f-af41-507e04452b81.pdf